tradingkey.logo

PharmaCyte Biotech Inc

PMCB
0.890USD
-0.027-2.99%
Cierre 11/04, 16:00ETCotizaciones retrasadas 15 min
6.05MCap. mercado
PérdidaP/E TTM

PharmaCyte Biotech Inc

0.890
-0.027-2.99%

Más Datos de PharmaCyte Biotech Inc Compañía

PharmaCyte Biotech, Inc. is a biotechnology company. It is focused on developing cellular therapies for cancer, diabetes, and malignant ascites based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Its product candidate is referred to as CypCaps. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used to produce various biologically active molecules. It is advancing clinical research and development of new cellular-based therapies in oncology and diabetes. It is also focused on developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. It is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant.

Información de PharmaCyte Biotech Inc

Símbolo de cotizaciónPMCB
Nombre de la empresaPharmaCyte Biotech Inc
Fecha de salida a bolsaSep 11, 2003
Director ejecutivoMr. Joshua N. (Josh) Silverman
Número de empleados2
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 11
Dirección3960 Howard Hughes Parkway, Suite 500
CiudadLAS VEGAS
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal89169
Teléfono19175952850
Sitio Webhttps://pharmacyte.com/
Símbolo de cotizaciónPMCB
Fecha de salida a bolsaSep 11, 2003
Director ejecutivoMr. Joshua N. (Josh) Silverman

Ejecutivos de PharmaCyte Biotech Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jonathan L. Schechter
Mr. Jonathan L. Schechter
Independent Director
Independent Director
50.00K
--
Mr. Carlos A. Trujillo, CPA
Mr. Carlos A. Trujillo, CPA
Chief Financial Officer
Chief Financial Officer
10.40K
--
Dr. Michael M. Abecassis, M.D.
Dr. Michael M. Abecassis, M.D.
Independent Director
Independent Director
--
--
Mr. Wayne R. Walker
Mr. Wayne R. Walker
Independent Director
Independent Director
--
--
Mr. Robert Weinstein
Mr. Robert Weinstein
Independent Director
Independent Director
--
--
Mr. Joshua N. (Josh) Silverman
Mr. Joshua N. (Josh) Silverman
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jonathan L. Schechter
Mr. Jonathan L. Schechter
Independent Director
Independent Director
50.00K
--
Mr. Carlos A. Trujillo, CPA
Mr. Carlos A. Trujillo, CPA
Chief Financial Officer
Chief Financial Officer
10.40K
--
Dr. Michael M. Abecassis, M.D.
Dr. Michael M. Abecassis, M.D.
Independent Director
Independent Director
--
--
Mr. Wayne R. Walker
Mr. Wayne R. Walker
Independent Director
Independent Director
--
--
Mr. Robert Weinstein
Mr. Robert Weinstein
Independent Director
Independent Director
--
--
Mr. Joshua N. (Josh) Silverman
Mr. Joshua N. (Josh) Silverman
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
--
--

Desglose de ingresos

Sin datos
Sin datos
Por negocio
Por región
Sin datos

Estadísticas de accionistas

Actualizado: sáb., 25 de oct
Actualizado: sáb., 25 de oct
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Intracoastal Capital, L.L.C.
7.76%
The Vanguard Group, Inc.
2.86%
Geode Capital Management, L.L.C.
1.86%
Equitec Proprietary Markets, LLC
1.22%
Asher (Daniel B)
1.22%
Otro
85.08%
Accionistas
Accionistas
Proporción
Intracoastal Capital, L.L.C.
7.76%
The Vanguard Group, Inc.
2.86%
Geode Capital Management, L.L.C.
1.86%
Equitec Proprietary Markets, LLC
1.22%
Asher (Daniel B)
1.22%
Otro
85.08%
Tipos de accionistas
Accionistas
Proporción
Corporation
7.76%
Investment Advisor
4.83%
Individual Investor
2.88%
Investment Advisor/Hedge Fund
2.44%
Hedge Fund
1.16%
Bank and Trust
0.05%
Otro
80.88%

Participación institucional

Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
61
576.91K
8.49%
-485.34K
2025Q2
66
1.28M
18.72%
-522.91K
2025Q1
71
1.30M
18.90%
-631.78K
2024Q4
75
1.52M
21.80%
-704.25K
2024Q3
81
1.75M
23.16%
-1.87M
2024Q2
84
1.91M
21.34%
-3.77M
2024Q1
81
1.85M
20.70%
-3.82M
2023Q4
82
1.98M
21.84%
-3.87M
2023Q3
81
2.90M
23.35%
-2.45M
2023Q2
83
2.99M
16.94%
-4.58M
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Intracoastal Capital, L.L.C.
527.38K
1.12%
--
--
Dec 31, 2024
The Vanguard Group, Inc.
194.45K
0.41%
-71.00
-0.04%
Jun 30, 2025
Geode Capital Management, L.L.C.
126.60K
0.27%
-12.33K
-8.88%
Jun 30, 2025
Equitec Proprietary Markets, LLC
82.73K
0.18%
--
--
Jun 30, 2025
Asher (Daniel B)
82.73K
0.18%
--
--
Dec 31, 2024
Schechter (Jonathan L)
50.00K
0.11%
--
--
Sep 15, 2025
Silverman (Joshua N.)
50.00K
0.11%
--
--
Sep 15, 2025
Renaissance Technologies LLC
49.80K
0.11%
+300.00
+0.61%
Jun 30, 2025
Susquehanna International Group, LLP
27.61K
0.06%
+9.20K
+49.98%
Jun 30, 2025
Schonfeld Strategic Advisors LLC
26.20K
0.06%
+700.00
+2.75%
Jun 30, 2025
Ver más

ETFs relacionados

Actualizado: dom., 2 de nov
Actualizado: dom., 2 de nov
Nombre
Proporción
iShares Micro-Cap ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
Proporción0%
Dimensional US Core Equity 1 ETF
Proporción0%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
KeyAI